Arcturus Therapeutics Holdings Inc (ARCT)

Currency in USD
8.63
-0.05(-0.58%)
Closed·
8.620.00(0.05%)
·
ARCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.618.93
52 wk Range
5.8524.17
Key Statistics
Prev. Close
8.68
Open
8.75
Day's Range
8.61-8.93
52 wk Range
5.85-24.17
Volume
316.42K
Average Vol. (3m)
479.53K
1-Year Change
-18.3538%
Book Value / Share
7.53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.30
Upside
+169.99%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Arcturus Therapeutics Holdings Inc SWOT Analysis


Pipeline Progress
Learn about Arcturus' advancing clinical trials in cystic fibrosis and OTC deficiency, with interim data expected to shape the company's future prospects
Strategic Partnerships
Delve into Arcturus' collaborations with CSL Seqirus and Meiji, positioning the company for significant revenue potential in vaccine distribution
Financial Outlook
Analysts project sales decline but extended cash runway to 2028. Average price target ranges from $41 to $140, reflecting diverse market perspectives
mRNA Pionee
Explore Arcturus Therapeutics' innovative self-amplifying mRNA technology and its potential to revolutionize therapeutics and vaccines
Read full SWOT analysis

Arcturus Therapeutics Holdings Inc Earnings Call Summary for Q4/2025

  • Arcturus reported Q4 2025 EPS of -$1.03 vs. $4.28 expected; revenue of $7.2M missed forecast of $232.52M by 96.9%, driving stock down 5.27% to $8.35.
  • Revenue decline attributed to reduced collaboration income and program transitions to commercial phase; company maintains $232.8M cash position.
  • Cash runway extends into Q2 2028, providing buffer as company focuses strategic efforts on rare disease clinical programs for future growth.
  • CEO Payne reaffirmed commitment to rare disease programs despite disappointing results; upcoming quarters forecast continued negative EPS amid execution challenges.
  • Key risks include ongoing revenue declines, high R&D expenses, commercial viability uncertainty, and potential regulatory hurdles for clinical programs.
Last Updated: 03/03/2026, 05:44 PM
Read Full Transcript

Compare ARCT to Peers and Sector

Metrics to compare
ARCT
Peers
Sector
Relationship
P/E Ratio
−3.8x−4.3x−0.5x
PEG Ratio
−0.190.090.00
Price / Book
1.2x2.5x2.6x
Price / LTM Sales
3.0x11.0x3.2x
Upside (Analyst Target)
136.2%46.0%47.6%
Fair Value Upside
Unlock2.7%6.1%Unlock

Analyst Ratings

10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 23.30
(+169.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
B.Riley
Buy22.00+154.92%-New CoverageMar 18, 2026
Canaccord
Buy21.00+143.34%66.00MaintainMar 05, 2026
Citi
Hold8.00-7.30%7.00MaintainMar 04, 2026
Roth/MKM
Buy20.00+131.75%-New CoverageJan 23, 2026
Citi
Hold7.00-18.89%9.00MaintainJan 06, 2026

Earnings

Latest Release
Mar 03, 2026
EPS / Forecast
-1.03 / 4.28
Revenue / Forecast
7.2M / 232.52M
EPS Revisions
Last 90 days

ARCT Income Statement

People Also Watch

824.01
LITE
-3.37%
13.030
RCAT
+3.09%
168.30
CRDO
+5.50%
308.20
COHR
-1.67%
21.73
SRPT
-1.90%

FAQ

What Is the Arcturus Therapeutics Holdings Inc (ARCT) Stock Price Today?

The Arcturus Therapeutics Holdings Inc stock price today is 8.63 USD.

What Stock Exchange Does Arcturus Therapeutics Holdings Inc Trade On?

Arcturus Therapeutics Holdings Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Arcturus Therapeutics Holdings Inc?

The stock symbol for Arcturus Therapeutics Holdings Inc is "ARCT."

What Is the Arcturus Therapeutics Holdings Inc Market Cap?

As of today, Arcturus Therapeutics Holdings Inc market cap is 245.86M USD.

What Is Arcturus Therapeutics Holdings Inc's Earnings Per Share (TTM)?

The Arcturus Therapeutics Holdings Inc EPS (TTM) is -2.40.

When Is the Next Arcturus Therapeutics Holdings Inc Earnings Date?

Arcturus Therapeutics Holdings Inc will release its next earnings report on May 11, 2026.

From a Technical Analysis Perspective, Is ARCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Arcturus Therapeutics Holdings Inc Stock Split?

Arcturus Therapeutics Holdings Inc has split 1 times.

How Many Employees Does Arcturus Therapeutics Holdings Inc Have?

Arcturus Therapeutics Holdings Inc has 109 employees.

What is the current trading status of Arcturus Therapeutics Holdings Inc (ARCT)?

As of Apr 15, 2026, Arcturus Therapeutics Holdings Inc (ARCT) is trading at a price of 8.63 USD, with a previous close of 8.68 USD. The stock has fluctuated within a day range of 8.61 USD to 8.93 USD, while its 52-week range spans from 5.85 USD to 24.17 USD.

What Is Arcturus Therapeutics Holdings Inc (ARCT) Price Target According to Analysts?

The average 12-month price target for Arcturus Therapeutics Holdings Inc is 23.30 USD, with a high estimate of 68 USD and a low estimate of 8 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +169.99% Upside potential.

What Is the ARCT Premarket Price?

ARCT's last pre-market stock price is 8.74 USD. The pre-market share volume is 2,370.00, and the stock has decreased by 0.06, or 0.69%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.